Innovent Biologics announced that its Phase 3 STAR study of efdamrofusp alfa for neovascular age-related macular degeneration (nAMD) in Chinese patients met the primary 52-week endpoint, showing vision improvement comparable to aflibercept. Notably, 73% of patients achieved a 16-week dosing interval, with nearly 60% potentially extending to 20 weeks, reducing treatment burden. The drug also showed a 50% lower incidence of macular atrophy compared to aflibercept, indicating potential protective benefits. Innovent plans to submit a New Drug Application and continue follow-up to confirm long-term effects.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
AmpliTech Group marked its fifth anniversary as a public company by ringing the Nasdaq opening bell and announcing record revenue of $25.2 million in fiscal 2025, a 165% increase year-over-year. The company, a US-based leader in RF and microwave sign...
